FDA’s Gottlieb draws those ‘gaming’ system into pricing debate

04:29 EDT 22 Jun 2017 | Pharmafile

President Trump spoke often of how pharmaceutical companies were ‘getting away with murder’, in regards to drug pricing, and now the FDA has hinted how it may seek to influence pricing, despite its limited protocol.

In reality, the FDA does not have a direct say on drug pricing – its role is to ensure that the drugs reaching the public are safe for use. However, Gottlieb, in a recent blog post of the FDA website, identified that certain companies had used regulatory rules to keep competitors from the market.

read more

Original Article: FDA’s Gottlieb draws those ‘gaming’ system into pricing debate


More From BioPortfolio on "FDA’s Gottlieb draws those ‘gaming’ system into pricing debate"

Quick Search


Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...